In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. RFA in breast cancer is a safe and promising minimally invasive treatment for tumors £ 2 cm in diameter. Combination of ultrasound-guided RFA of breast cancer with concurrent sentinel lymph node biopsy could potentially become state-of-the-art breast-conservative therapy for early breast cancer. Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or c 2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10%) than in those with initial tumors 2 cm (8 of 355, 2.3%; P ¼ .015). IBTR-free rates 5 years after RFA were 97%, 94%, and 87% in patients with initial tumor sizes 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.
Introduction
Technological innovations have offered new minimally invasive therapeutic alternatives to surgery in several types of cancer. Nonsurgical ablation, especially radiofrequency ablation (RFA), plays a major role in the treatment of hepatic cancer, 1 renal cell carcinoma, 2 lung cancer, 3, 4 bone metastases, 5 and various other solid tumors. 6, 7 Clinical research on various minimally invasive therapies for breast cancer has been conducted in the past decade. Several studies have reported on the feasibility of RFA followed by surgery, [8] [9] [10] [11] [12] [13] [14] [15] [16] as well as RFA alone, [17] [18] [19] [20] for early-stage breast cancer. Although various ablation methods are available (eg, high-intensity focused ultrasound and cryo-, laser, or microwave ablation), a recent meta-analysis showed that RFA appears to be the most effective. 21 The Breast Cancer Society for Minimally Invasive Therapy was founded in 2005 to investigate optimized treatment of early breast cancer and conducted a retrospective study of the feasibility, safety, and outcomes of RFA without surgery for the treatment of early-stage breast cancer.
Patients and Methods

Patients
Patients with breast cancer who were treated with RFA between July 2003 and June 2009 at 10 institutions were included in the study. Inclusion criteria were as followed: at least 18 years of age, biopsy-proven breast cancer, a candidate of RFA due to physician's discretion or patient's refusal of operation, and largest tumor diameter 3.5 cm as measured by ultrasound and/or magnetic resonance imaging (MRI). Breast cancer with multifocal lesions or extensive intraductal spread like diffuse calcification was excluded. Patients who received primary systemic chemotherapy were also excluded. RFA in breast cancer had been considered an experimental treatment and it was performed with approval of the institutional review board at each participating institution. Written informed consent was obtained from all patients before the RFA procedure.
In all patients, core needle biopsy (CNB) and/or vacuum-assisted biopsy (VAB) were performed preoperatively to evaluate the pathologic diagnosis of the breast tumor. In most patients, the viability of the ablated tumor tissue was examined after RFA with hematoxylin and eosin staining and/or nicotine-amide adenine dinucleotide-diaphorase (NADH-diaphorase) staining.
22-25
RFA Procedure
For the patients included in the retrospective analysis, several kinds of RFA electrodes and generators, as well as technical procedures, were used. However, the fundamental aspects of the RFA procedure, such as electrode insertion under ultrasound guidance and maintenance of a high temperature in the referent tumor during ablation, were similar in every RFA procedure across institutions and only ultrasound-guided RFA was performed.
Before RFA, a sentinel lymph node biopsy was performed under general anesthesia. If evidence of metastasis was detected in frozen sections of the sentinel lymph node, axillary lymph node dissection was performed. Two large dispersive electrodes (ground pads) were placed on the patient's thighs. All patients underwent breast ultrasound preoperatively to determine, as it would facilitate ultrasoundguided RFA. The skin entry site was chosen that allowed the safest path and avoided breast vessels. The needle was placed into the target tumor, and its correct placement was verified using multiplanar image reconstructions. Approximately 20 to 40 mL 5% glucose solution was injected into the retromammary space around the tumor to avoid burns of the major pectoral muscle from RFA-induced heat. RF energy was applied to the tissue with an initial power setting and subsequently increased. The appearance and progression of hyperechogenicity on ultrasound was used to guide the therapy. RFA was applied until the tumor was completely hyperechoic, with the aim to obtain a safety margin of at least 0.5 cm around the tumor. After completion of the RFA procedure, ultrasound was performed to assess technical success and to detect any complications.
Follow-up, Adjuvant Therapy, and Imaging Diagnosis After RFA Most patients were followed up 1 month after RFA treatment, and then at 6-or 12-month intervals thereafter. At each follow-up visit, patients usually underwent an imaging study of ultrasound, MRI, and/or mammography for assessment of the ablated breast. Decisions regarding adjuvant systemic therapy were based on the status of the sentinel lymph node, tumor size, and intrinsic subtype status as determined by the pretreatment biopsy diagnosed from the tumor specimens before RFA.
Clinicopathological Factors for Ipsilateral Breast Tumor Recurrence
The following preoperative factors were evaluated: patient age, imaging modality used for assessing tumor distribution, histological subtype, technique used for sampling tumor tissue submitted for pathological evaluation, tumor size, and biological marker status (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor type 2 [HER2]). The intraoperative factors evaluated were total ablation time, temperature of the tumor just after ablation, and type of RFA electrode used. The postoperative factors evaluated were imaging and pathologic modalities, timing of tissue sampling for the assessment of tumor viability, lymph node status, adjuvant radiotherapy, and adjuvant systemic therapy.
Statistical Analysis
The c 2 test or Fisher exact test was used to evaluate the association between each clinicopathological factor and ipsilateral breast tumor recurrence (IBTR). Local recurrence-free survival was estimated using the Kaplan-Meier method and was compared among subgroups using the log-rank test. The level of significance was set at P < .05 (2-tailed). All statistical analyses were performed using SPSS software version 17.0.
Results
A total of 386 patients with breast cancer who were treated with RFA alone between July 2003 and June 2009 at the 10 participating institutions were retrospectively identified. The patients' characteristics are summarized in Table 1 . The median age was 54 years (range, 22-92 years). The mean tumor size was 1.6 cm in diameter. A total of 356 (92%) patients had a tumor size 2 cm in diameter. The pathologic diagnosis was invasive ductal carcinoma in 334 patients, invasive lobular carcinoma in 10, and other in 42.
The cool-tip radiofrequency system, 26 LeVeen needle electrode system, 1 and the RITA system 27 were used for RFA treatment of breast cancer. Of the 386 patients, 356 (92%) received RFA treatment using the cool-tip system. The mean required time for the ablation procedure was 19 minutes (range, 4-72 minutes), and the mean temperature of the tumor just after ablation was 91 C.
After RFA, MR images showed that the enhancing lesion has disappeared and a specific peripheral enhancement was clearly visible (Figure 1) . Figure 2 revealed an excellent result case after RFA.
No procedure-related deaths occurred. In terms of RFA-related adverse events, local pain was observed in 9 patients (2.3%), skin
Radiofrequency Ablation of Breast Cancer burn in 15 patients (3.9%), and nipple retraction in 7 patients (1.8%) ( Table 2 ). No differences in adverse events were observed according to tumor size (data not shown).
Forty-three patients had positive axillary lymph nodes. A total of 348 patients (90%) received adjuvant therapy; of these, 292 received endocrine therapy, 25 received chemotherapy, and 31 received both therapies; 352 (91%) also received breast irradiation.
The median follow-up period was 50 months (range, 3-92 months). IBTR was more frequently observed in patients with a tumor size > 2 cm (3 of 30, 10%) than in patients with a tumor size 2 cm (6 of 356, 2%; P < .001). The IBTR-free survival rate at 5 years after RFA was 97%, 94%, and 87% in patients with a tumor size 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. The local recurrence rate after RFA was higher in tumors without irradiation than in those with irradiation (18.2% vs. 3.2%; P < .001) (Figure 3) .
IBTR after RFA tended to occur more frequently in patients with ER-negative tumors (3 of 43, 7%) compared with patients with ERpositive tumors (8 of 343, 2.3%; P ¼ .059; Table 3 ). No significant differences in IBTR were seen between patients with HER2-positive tumors (1 of 30, 3.3%) and HER2-negative tumors (9 of 325, 2.8%; P ¼ .858).
Discussion
In this study, we retrospectively investigated the clinical utility of percutaneous RFA as a minimally invasive treatment option for early-stage breast cancer. RFA is recognized to be less invasive than surgery for many diseases and solid cancers. For example, RFA for hepatocellular carcinoma and coronary catheter ablation for atrial fibrillation have been adopted worldwide. Many investigators have attempted feasibility studies on RFA followed by breast surgery [7] [8] [9] [10] [11] [12] 15, 16 ; however, RFA without resection for breast carcinoma is still being investigated.
For ablative therapies to be successful, accurate preoperative assessment of the tumor, including intraductal spread, is critical, as is the accurate assessment of treatment response after RFA. B-mode ultrasound imaging can be informative when used before and after RFA, as RFA for breast cancer is performed under ultrasound guidance. Breast MRI also has considerable potential for pre-and post-RFA assessment. 19, 28 Many studies have used MRI as the gold standard for assessing the response to RFA treatment for breast cancer. [17] [18] [19] There are several technical issues associated with RFA for breast cancer. First, it is difficult to determine the optimum zone of ablation and duration of ablation because of intraductal spread. Second, it is challenging to accurately assess the tumor margin. Third, unambiguously determining the optimum sampling site 
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Clinical Breast Cancer August 2018 -e497 within the ablated tissue poses a problem. Therefore, the viability of tissue collected from the zone of ablation by VAB or CNB should be assessed. Although many reports have used NADH-diaphorase staining for the assessment of tissue viability, it is a complex procedure that requires freezing of tissue samples in advance. Additional assessment using MRI or other imaging modalities before and after RFA may be important, as only part of the zone of ablation is assessed in the collected tissues. In this study, breast tumors 2 cm in diameter were shown to be promising candidates for RFA (Figure 3) . Based on the subset analysis, most patients who had luminal-type breast cancer did not develop IBTR in follow-up. Hormone receptorenegative, HER2-positive, or triple-negative breast cancers tended to be more progressive, and primary chemotherapy should be indicated for these patients rather than RFA. Invasive lobular carcinoma tends to spread widely in the mammary ducts, and RFA may be contraindicated in these patients. 28 In our study, IBTR tended to be more common in patients with ER-negative tumors than in those with ER-positive tumors (Table 3) . Recently developed breast-conserving treatment strategies for breast cancer consist of adequate breast surgery, appropriate adjuvant therapy, and breast irradiation. In this study, breast irradiation after RFA was associated with significantly fewer cases of IBTR. Thus, RFA should not be offered to patients without also performing radiation therapy. The most common complication reported with RFA for breast cancer is skin burns, which was the most common adverse event in the present study, followed by nipple retraction. We placed ice packs on any affected areas to minimize the effects of skin burns and injected 5% glucose solution into the retromammary space to avoid burns of the major pectoral muscle from RFA-induced heat. Induration is often palpable after RFA, but this is thought to be due to fibrosis around the zone of ablation after completion of RFA. Induration is not necessarily regarded as an adverse event, like burns, as it is affected by factors such as breast size and tumor location.
Limitations of our study include the retrospective design and lack of randomization. Furthermore, IBTR was not documented for different types of chemo/endocrine therapy, thus restricting the analysis of this feature. Finally, no analyses were performed to ascertain whether adjuvant chemotherapy or endocrine therapy had any influence on outcomes. However, to our knowledge, it is the first report analyzed in many patients treated with RFA alone.
In conclusion, combination of ultrasound-guided RFA of breast cancer with concurrent sentinel lymph node biopsy could potentially become state-of-the-art breast-conservative therapy for early breast cancer.
A prospective study is needed for the application of ultrasoundguided RFA for small breast carcinoma.
Clinical Practice Points
Several studies have reported on the feasibility of RFA followed by surgery, as well as RFA alone, for early-stage breast cancer. RFA in breast cancer is a safe and promising minimally invasive treatment for tumors 2 cm in diameter. Combination of ultrasound-guided RFA of breast cancer with concurrent sentinel lymph node biopsy should be considered a potentially effective option for early breast cancer.
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